Cargando…
FRI069 Treatment With Mibavademab, A Novel Leptin Receptor Agonist, Is Associated With Improvement In Weight And Associated Comorbidities In Congenital Leptin Deficiency
Disclosure: E. Ozsu: None. L. Akin: None. M. Aydin: None. M. Berberoglu: None. D. Stein: Employee; Self; Regeneron Pharmaceuticals. Stock Owner; Self; Regeneron Pharmaceuticals. O. Pagovich: Employee; Self; Regeneron Pharmaceuticals. Stock Owner; Self; Regeneron Pharmaceuticals. B. Olenchock: Employ...
Autores principales: | Ozsu, Elif, Akin, Leyla, Aydin, Murat, Berberoglu, Merih, Stein, David, Pagovich, Odelya, Olenchock, Ben, Podgrabinska, Simona, Harris, Charles Andrew, Mendell, Jeanne, SinhaRoy, Ranabir, Altarejos, Judith, Akinci, Baris, Oral, Elif A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554460/ http://dx.doi.org/10.1210/jendso/bvad114.079 |
Ejemplares similares
-
FRI057 Drug Concentrations And Dosing Considerations For Mibavademab, A Novel Leptin Receptor Agonist, In Individuals With Generalized Lipodystrophy
por: Mendell, Jeanne, et al.
Publicado: (2023) -
FRI059 Long-term Follow-up On Partial Lipodystrophy Treated With Leptin Receptor Agonist Mibavademab(REGN4461)
por: Foss de Freitas, Maria Cristina, et al.
Publicado: (2023) -
FRI058 Treatment With Mibavademab, A Novel Leptin Receptor Agonist, Is Associated With Improvement In Metabolic Parameters In Individuals With Generalized Lipodystrophy
por: Olenchock, Ben, et al.
Publicado: (2023) -
OR33-02 The Treatment of Partial Lipodystrophy in the Setting of Neutralizing Antibody Against Metreleptin with Leptin Receptor Agonist REGN4461
por: Akinci, Baris, et al.
Publicado: (2020) -
FRI039 Endothelial Dysfunction Is Associated With Adiponectin And Leptin In Adolescents With PCOS
por: Gavryutina, Irina, et al.
Publicado: (2023)